Does CYTARABINE Cause Second primary malignancy? 409 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 409 reports of Second primary malignancy have been filed in association with CYTARABINE (cytarabine). This represents 0.9% of all adverse event reports for CYTARABINE.
409
Reports of Second primary malignancy with CYTARABINE
0.9%
of all CYTARABINE reports
203
Deaths
98
Hospitalizations
How Dangerous Is Second primary malignancy From CYTARABINE?
Of the 409 reports, 203 (49.6%) resulted in death, 98 (24.0%) required hospitalization, and 45 (11.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CYTARABINE. However, 409 reports have been filed with the FAERS database.
What Other Side Effects Does CYTARABINE Cause?
Febrile neutropenia (6,142)
Off label use (4,183)
Pyrexia (2,992)
Neutropenia (2,558)
Disease progression (2,352)
Drug ineffective (2,281)
Thrombocytopenia (2,148)
Sepsis (2,013)
Myelosuppression (1,869)
Product use in unapproved indication (1,619)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which CYTARABINE Alternatives Have Lower Second primary malignancy Risk?
CYTARABINE vs CYTARABINE\DAUNORUBICIN
CYTARABINE vs DABIGATRAN
CYTARABINE vs DABIGATRAN ETEXILATE
CYTARABINE vs DABRAFENIB
CYTARABINE vs DABRAFENIB\TRAMETINIB